DK1421105T3 - Anti-cancer cyclopenta[g]quinazolinforbindelser - Google Patents

Anti-cancer cyclopenta[g]quinazolinforbindelser

Info

Publication number
DK1421105T3
DK1421105T3 DK02755281.9T DK02755281T DK1421105T3 DK 1421105 T3 DK1421105 T3 DK 1421105T3 DK 02755281 T DK02755281 T DK 02755281T DK 1421105 T3 DK1421105 T3 DK 1421105T3
Authority
DK
Denmark
Prior art keywords
alkyl
cyclopenta
cancer
halogenoalkyl
cyanoalkyl
Prior art date
Application number
DK02755281.9T
Other languages
English (en)
Inventor
Ann Lesley Jackman
Vassilios Bavetsias
Original Assignee
Btg Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0121151A external-priority patent/GB0121151D0/en
Priority claimed from GB0129387A external-priority patent/GB0129387D0/en
Application filed by Btg Int Ltd filed Critical Btg Int Ltd
Application granted granted Critical
Publication of DK1421105T3 publication Critical patent/DK1421105T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • C07D239/90Oxygen atoms with acyclic radicals attached in position 2 or 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0215Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK02755281.9T 2001-08-31 2002-08-30 Anti-cancer cyclopenta[g]quinazolinforbindelser DK1421105T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0121151A GB0121151D0 (en) 2001-08-31 2001-08-31 Anti-cancer compounds
GB0129387A GB0129387D0 (en) 2001-12-07 2001-12-07 Anti-cancer compounds
US34025301P 2001-12-18 2001-12-18
PCT/GB2002/003979 WO2003020748A1 (en) 2001-08-31 2002-08-30 Anti-cancer cyclopenta[g]quinazoline compounds

Publications (1)

Publication Number Publication Date
DK1421105T3 true DK1421105T3 (da) 2010-11-29

Family

ID=27256270

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02755281.9T DK1421105T3 (da) 2001-08-31 2002-08-30 Anti-cancer cyclopenta[g]quinazolinforbindelser

Country Status (15)

Country Link
US (6) US7297701B2 (da)
EP (3) EP2332962A1 (da)
JP (1) JP4328202B2 (da)
KR (2) KR100983962B1 (da)
AT (1) ATE483722T1 (da)
AU (1) AU2002321576B2 (da)
BR (1) BRPI0212215B8 (da)
CA (1) CA2458813C (da)
CY (1) CY1111078T1 (da)
DE (1) DE60237902D1 (da)
DK (1) DK1421105T3 (da)
MX (1) MXPA04001905A (da)
PT (1) PT1421105E (da)
WO (1) WO2003020748A1 (da)
ZA (1) ZA200401587B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100983962B1 (ko) * 2001-08-31 2010-09-27 비티지 인터내셔널 리미티드 항암제로서 사용되는 시클로펜타[g]퀴나졸린 화합물
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
CA2655933C (en) 2006-06-23 2014-09-09 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in cancer
CN101977620B (zh) * 2008-03-18 2014-05-07 英国技术集团国际有限公司 用于治疗类风湿性关节炎或急性骨髓性白血病的环戊二烯并[g]喹唑啉衍生物
KR20110084280A (ko) 2008-11-03 2011-07-21 알레시아 바이오쎄라퓨틱스 인코포레이티드 종양 항원의 생물 활성을 특이적으로 차단하는 항체
US8809526B2 (en) * 2010-07-19 2014-08-19 Onyx Pharmaceuticals, Inc. Synthesis of cyclopentaquinazolines
CN103748106A (zh) * 2010-12-22 2014-04-23 奥尼克斯医药品股份有限公司 有效的肽偶联及其在环戊二烯并[g]喹唑啉三钠盐的合成和分离中的用途
RS59080B1 (sr) 2011-03-31 2019-09-30 Adc Therapeutics Sa Antitela protiv antigena 1 povezanog sa bubrezima i njihovi fragmenti koji se vezuju za antigen
HRP20190946T1 (hr) 2012-01-09 2019-07-26 Adc Therapeutics Sa Sredstva za liječenje trostruko negativnog raka dojke
GB201707864D0 (en) * 2017-05-16 2017-06-28 Inst Of Cancer Research: Royal Cancer Hospital Platinum-reistant cancer treatment

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3069468D1 (en) 1979-12-19 1984-11-22 Nat Res Dev Quinazoline derivatives, processes for their preparation, compositions containing them and their use as anti-cancer agents
GB8607683D0 (en) 1986-03-27 1986-04-30 Ici Plc Anti-tumor agents
GB9205320D0 (en) 1992-03-11 1992-04-22 Ici Plc Anti-tumour compounds
GB9223352D0 (en) * 1992-11-06 1992-12-23 Ici Plc Tricyclic compounds
GB9408936D0 (en) * 1994-05-05 1994-06-22 Cancer Res Inst Anti-cancer compounds
JPH1166841A (ja) * 1997-08-22 1999-03-09 Mitsubishi Electric Corp 半導体記憶装置
KR100303775B1 (ko) * 1998-10-28 2001-09-24 박종섭 디디알 에스디램에서 데이터스트로브신호를 제어하기 위한 방법및 장치
GB9904275D0 (en) * 1999-02-24 1999-04-21 Cancer Res Campaign Tech Anti-cancer compounds
JP3416083B2 (ja) * 1999-08-31 2003-06-16 株式会社日立製作所 半導体装置
JP2002007200A (ja) * 2000-06-16 2002-01-11 Nec Corp メモリ制御装置及び動作切替方法並びにインターフェース装置、半導体集積チップ、記録媒体
EP1420809B1 (en) 2001-08-31 2011-09-28 BTG International Limited Use of cyclopenta[g]quinazoline derivatives for treating cancer
KR100983962B1 (ko) * 2001-08-31 2010-09-27 비티지 인터내셔널 리미티드 항암제로서 사용되는 시클로펜타[g]퀴나졸린 화합물
KR100568546B1 (ko) * 2004-10-19 2006-04-07 삼성전자주식회사 메모리 시스템, 반도체 메모리 장치, 및 이 시스템과장치의 출력 데이터 스트로우브 신호 발생 방법
KR100755371B1 (ko) * 2005-05-03 2007-09-04 삼성전자주식회사 반도체 메모리 장치 및 이 장치의 데이터 스트로우브 신호발생방법

Also Published As

Publication number Publication date
BRPI0212215B1 (pt) 2019-02-19
US7863284B2 (en) 2011-01-04
PT1421105E (pt) 2010-12-07
US20100056551A1 (en) 2010-03-04
BR0212215A (pt) 2004-09-21
US20100273817A1 (en) 2010-10-28
CA2458813A1 (en) 2003-03-13
CA2458813C (en) 2011-11-01
ATE483722T1 (de) 2010-10-15
US7297701B2 (en) 2007-11-20
WO2003020748A1 (en) 2003-03-13
ZA200401587B (en) 2005-05-25
US20100216824A1 (en) 2010-08-26
DE60237902D1 (de) 2010-11-18
US7705006B2 (en) 2010-04-27
AU2002321576B2 (en) 2008-09-11
MXPA04001905A (es) 2005-04-19
EP1421105A1 (en) 2004-05-26
US8552016B2 (en) 2013-10-08
EP2311850A1 (en) 2011-04-20
KR20100043294A (ko) 2010-04-28
US8063056B2 (en) 2011-11-22
US20080015206A1 (en) 2008-01-17
US8486955B2 (en) 2013-07-16
JP4328202B2 (ja) 2009-09-09
KR20040044511A (ko) 2004-05-28
EP1421105B1 (en) 2010-10-06
CY1111078T1 (el) 2015-06-11
US20040242606A1 (en) 2004-12-02
BRPI0212215B8 (pt) 2021-07-27
KR100983962B1 (ko) 2010-09-27
JP2005509600A (ja) 2005-04-14
US20090023760A1 (en) 2009-01-22
EP2332962A1 (en) 2011-06-15

Similar Documents

Publication Publication Date Title
CY1111078T1 (el) Αντικαρκινικες ενωσεις κυκλοπεντα[g]κιναζολινων
CY1112143T1 (el) Χρηση παραγωγων kykλοπenta[g]kinαζολινης για θεραπεια καρκινου
WO2002018383A3 (en) Aza heterocyclic derivatives and their therapeutic use
EP1447405A4 (en) CHINOLIN OR CHINAZOLINE DERIVATIVES THAT PREVENT THE AUTOPHOSPHORYLATION OF RECEPTORS FOR THE FIBROBLAST GROWTH FACTOR
WO2003106428A8 (fr) Derives d'arylsulfonamides et leur utilisation en tant que antagonistes au recepteur b1 de la bradykinine
NO983970L (no) Tricykliske forbindelser, deres fremstilling og anvendelse
BR0100318A (pt) Compostos de uracila e uso dos mesmos
ATE449083T1 (de) Chinazolin-derivate und ihre verwendung als arzneimittel
AR072756A2 (es) Intermediarios para la preparacion; derivados de triazolo[4,5-d]pirimidina, utiles como antitromboticos
PT1140851E (pt) 4-oxo-1,4-di-hidro-3-quinolinacarboxamidas como agentes antivirais
NO20022683L (no) Ureaforbindelser med muskarinisk reseptor-antagonistaktivitet
DE69709532D1 (de) 1-Phenyl-Pyrazolderivate und ihr Verwendung als Schädlingsbekämpfungsmittel
ATE556715T1 (de) Cyclopenta-äg-üchinazolin-derivate zur behandlung von arthritis oder akuter myeloischer leukämie
EP0979821A4 (en) TRICYCLIC CONNECTIONS
NO20071921L (no) Fremgangsmater for behandling av epileptogenese og epilepsi
YU67703A (sh) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju poremećaja kretanja
MY138156A (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
DK0759027T3 (da) Bicykliske amidinderivater som inhibitorer af nitrogenoxidsynthetase
TR200001950T2 (tr) İkameli 2-benzilamino-2-fenil-asetamid bileşikler.
BR0213731A (pt) Compostos de silìcio
MY133370A (en) Carbamate compounds for use in preventing or treating bipolar disorders
WO2009135673A3 (en) Compounds with glycidic structure active in the therapy of systemic and local inflammation
BR0114812A (pt) Derivados de 2-pirimidinilóxi-n-aril-benzilamina, seus processos de preparo e uso
YU67903A (sh) Karbamatna jedinjenja za upotrebu u sprečavanju ili lečenju anksioznih poremećaja
DK640889D0 (da) Fenylderivater med antidiabetisk, isaer hypoglykaemisk virkning